Veopoz’s approval was based on the data from the open-label Phase II/III trial (NCT04209634) consisting of ten participants. Image Credit: lev radin / Shutterstock.
Veopoz is the first drug which has been approved by the FDA for CD55 deficiency with hyperactivation of complement, angiopathic thrombosis, and protein-losing enteropathy or CHAPLE disease in patients aged one year and older.
ReportsLOA and PTSR Model - Docetaxel Albumin Bound in Fallopian Tube Cancer GlobalData
View allCompanies IntelligenceBayer AGRegeneron Pharmaceuticals IncAlnylam Pharmaceuticals IncRegeneron GmbHView all
CHAPLE is a genetic immune disease caused by mutations in the CD55 gene causing overactivation of the complement system. This results in impaired inflammatory response and causes symptoms such as abdominal pain, recurrent infections, oedema, and diarrhoea.
Veopoz, a monoclonal antibody, targets and inhibits the protein involved in the activation of the complement system, the C5 complement factor.
Veopoz’s approval was based on the data from the open-label Phase II/III trial (NCT04209634) consisting of 10 participants, who all achieved the primary outcome of normalised serum albumin at 12 weeks, with the patients maintaining these levels over 72 weeks of treatment.
At 48 weeks, only one patient required an albumin transfusion, compared to the period of 48 weeks before starting treatment, when five patients required a total of 60 transfusions. Additionally, two patients were hospitalised for seven days in 48 weeks after starting treatment, compared to nine patients requiring hospitalisation for a cumulative 268 days in the period before starting treatment. Veopoz is administered through a 30mg/kg intravenous loading dose, followed by weekly weight-based subcutaneous doses.
Approved therapies for rare diseases have increased in numbers in recent years, with GlobalData forecasting at least 35 US FDA approval in the rare disease areas in 2023.
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.